LONDON: Sanofi Pasteur, Sanofi's vaccines unit, said on Tuesday that its dengue vaccine, Dengvaxia, had received market approval in eleven countries.
To date the vaccine has been approved in Mexico, the Philippines, Brazil, El Salvador, Costa Rica, Paraguay, Guatemala, Peru, Indonesia, Thailand and Singapore, the statement said.
Dengue fever is a mosquito-borne disease caused by four virus serotypes (1 to 4) as categorized by the World Health Organisation. Overall, the disease is seen as a threat to about half of the world's population. Some 400 million people are believed to be infected annually.
-
Antioxidants found to be protective agents against cognitive decline -
Coffee reduces cancer risk, research suggests -
Keto diet emerges as key to Alzheimer's cure -
What you need to know about ischemic stroke -
Shocking reason behind type 2 diabetes revealed by scientists -
Simple 'finger test' unveils lung cancer diagnosis -
Groundbreaking treatment for sepsis emerges in new study -
All you need to know guide to rosacea